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Here we provide evidence that RBBP4 modulates te-
mozolomide (TMZ) sensitivity through coordinate
regulation of two key DNA repair genes critical for re-
covery from TMZ-induced DNA damage: methylgua-
nine-DNA-methyltransferase (MGMT) and RAD51.
Disruption of RBBP4 enhanced TMZ sensitivity,
induced synthetic lethality to PARP inhibition, and
increased DNA damage signaling in response to
TMZ. Moreover, RBBP4 silencing enhanced TMZ-
induced H2AX phosphorylation and apoptosis in
GBM cells. Intriguingly, RBBP4 knockdown sup-
pressed the expression ofMGMT, RAD51, and other
genes in association with decreased promoter H3K9
acetylation (H3K9Ac) and increased H3K9 tri-methyl-
ation (H3K9me3). Consistent with these data, RBBP4
interacts with CBP/p300 to form a chromatin-modi-
fying complex that binds within the promoter of
MGMT, RAD51, and perhaps other genes. Globally,
RBBP4 positively and negatively regulates genes
involved in critical cellular functions including tu-
morigenesis. The RBBP4/CBP/p300 complex may
provide an interesting target for developing ther-
apy-sensitizing strategies for GBMand other tumors.INTRODUCTION
Glioblastoma (GBM) is the most common and aggressive
primary brain tumor, which is routinely managed by surgery, ra-
diation (RT), and temozolomide (TMZ) chemotherapy. TMZ
cytotoxicity is predominantly mediated by O6-methylguanine
(O6-MG) DNA lesions, which are repaired by the DNA repair
protein MGMT (Drabløs et al., 2004). Consequently, GBM pa-
tients whose tumors express low-level MGMT, due to promoter
hypermethylation, are more responsive to TMZ-based therapyCell(Hegi et al., 2004; Stupp et al., 2009). Unfortunately, even these
patients with MGMT promoter hypermethylation develop TMZ
resistance and the majority die within 2 years (Hegi et al.,
2005). We and others have shown that TMZ resistance can
be induced by MGMT re-expression in a subset of MGMT-hy-
permethylated patients (Cahill et al., 2008; Gaspar et al., 2010;
Kitange et al., 2012; Yip et al., 2009) and that MGMT-depen-
dent and -independent resistance mechanisms can emerge in
the same patient-derived xenograft model. In this model, co-
administration of TMZ and a histone deacetylase dramatically
shifts the mechanism of resistance emergence toward MGMT
overexpression (Kitange et al., 2012). These latter data suggest
that emergence of TMZ resistance can be mediated at an
epigenetic level, and, to identify underlying epigenetic mecha-
nisms associated with TMZ resistance, we used a small hairpin
RNA (shRNA) library screen to identify genes regulating TMZ
responsiveness. Using this approach, we identified retinoblas-
toma binding protein 4 (RBBP4) as a potential modulator of
TMZ response.
The RBBP4 gene encodes a protein that is a component of
several chromatin-modifying protein complexes with varying ef-
fects on gene expression (reviewed in Wolffe et al., 2000).
RBBP4 contributes to repression of gene transcription as a
key member of the nucleosome remodeling and deacetylation
(NURD) complex, polycomb repressor complex 2 (PRC2), and
SIN3- chromatin-modulating complexes (Kuzmichev et al.,
2002; Todd and Picketts, 2012; Vermaak et al., 1999). As a
member of the chromatin assembly factor 1 (CAF1) complex,
RBBP4 regulates chromatin assembly in normal replication
and during repair of DNA damage (Furuyama et al., 2006;
Zhang et al., 2013). Finally, in a complex with p300/CBP,
RBBP4 activates gene transcription through histone acetylation
(Zhang et al., 2000). To date, we are unaware of any studies
that have directly implicated this protein in the modulation of
chemosensitivity. This paper reports that RBBP4 is a negative
modulator of TMZ sensitivity and that disruption of this protein
enhances TMZ sensitivity through downregulation of MGMT
and genes involved in homologous recombination (HR),
including RAD51.Reports 14, 2587–2598, March 22, 2016 ª2016 The Authors 2587
Figure 1. RBBP4 Modulates TMZ Sensitivity
in GBM Cells
(A) Absolute levels of RBBP4 shRNA in GBM22
cells following treatment with either DMSO or TMZ
are shown.
(B) Effect of RBBP4 siRNA, with and without TMZ
treatment, on the primary neurosphere (NS) for-
mation in GBM12 and GBM22 cells is shown.
(C) RBBP4 expression in T98G cells stably ex-
pressing shNT and four different RBBP4 shRNA
lentiviral constructs (upper panel) and in vitro TMZ
cytotoxicity CyQuant assay in the same cell con-
structs (lower panel) are shown.
(D) Effect of control shNT and four different RBBP4
shRNA on RBBP4 levels in U138 GBM cells (upper
panel) and in vitro cytotoxicity. Shown are the data
from three independent experiments conducted in
triplicate (error bar, SEM; *p < 0.05).RESULTS
Genome-wide shRNA Screen Identified RBBP4 as a
Modulator of TMZ Sensitivity
Since resistance is a major hurdle to successful TMZ therapy in
GBM, we conducted a high-throughput screening to identify po-
tential drivers of TMZ sensitivity in GBM. To that end, we used a
pooled shRNA library to identify genome-wide modulators of
TMZ response in short-term cultured cells from the GBM22 pa-
tient-derived xenograft model (Carlson et al., 2011). While this
approach identified several candidate genes (data not shown),
RBBP4 was particularly interesting because of our ongoing
work focused on understanding the epigenetic mechanisms of
TMZ resistance (Kitange et al., 2009a, 2012). The RBBP4 shRNA
amplification signal enrichment was significantly higher in
DMSO-treated than in TMZ-treated GBM22 cells (p < 0.0001)
(Figure 1A), suggesting enhanced TMZ efficacy in cells express-
ing RBBP4 shRNA. To confirm these results, we evaluated
whether small interfering RNA (siRNA) disruption of RBBP4
would sensitize MGMT hypermethylated patient-derived2588 Cell Reports 14, 2587–2598, March 22, 2016 ª2016 The AuthorsGBM12 and GBM22 cells to TMZ
in vitro. Consistently, RBBP4 siRNA, but
not the control non-specific targeting
(NT) siRNA, induced TMZ sensitization in
GBM22 cells following treatment with
10 mM TMZ (p < 0.01), and even more
profound sensitizing effects were seen in
GBM12 (p = 0.002) (Figure 1B). Thus,
RBBP4 can modulate TMZ response in
GBM cells lacking MGMT expression.
RBBP4 Disruption Sensitizes
MGMT-Expressing GBM Cells
to TMZ
Next we evaluated whether RBBP4 can
modulate TMZ response in MGMT unme-
thylated T98G and U138 GBM cell lines
using four RBBP4 shRNA constructs
(RBBP4-1 to -4) and a single NT shRNA.All four shRNA constructs significantly silenced RBBP4 in both
T98G and U138 cells (Figures 1C and 1D, upper panels). More-
over, all four different RBBP4 shRNA constructs significantly
sensitized T98G and U138 cells to TMZ as compared to the NT
shRNA (Figures 1C and 1D, lower panels). The relative fluores-
cence for T98G-expressing NT shRNA (T98GNT) treated with
100 mM TMZ was significantly higher compared with all four
RBBP4 shRNA clones (Figure 1C, lower panel; p < 0.001). Similar
significant sensitization was observed in TMZ-treated (300 mM)
U138shRBBP4 clones compared with the control U138shNT
cells (Figure 1D, lower panel; p < 0.001) and GBM6shRBBP4
cells (p < 0.05; see Figure S6C). Therefore, RBBP4 is a negative
modulator of TMZ response, and silencing of this protein en-
hances the sensitivity in both MGMT-expressing and non-ex-
pressing GBM cells.
RBBP4 Regulates TMZ Sensitivity by Modulating MGMT
Expression
The above finding that RBBP4 is involved in the regulation of
TMZ response in MGMT-expressing GBM cells has not been
Figure 2. RBBP4 Regulates TMZ Sensitivity
through Modulation of MGMT Expression
in GBM Cells
(A) Real-time PCR evaluates RBBP4 and MGMT
expression using total RNA extracted from T98G
cells expressing control shNT and four different
constructs of RBBP4 shRNA.
(B) A representative western blot depicts RBBP4
and MGMT protein levels in T98G cells expressing
NT-shRNA and two RBBP4 shRNA constructs.
(C) Effects of MGMT inhibitor O6-BG on
TMZ sensitivity in T98G cells expressing control
shNT and two RBBP4 shRNA (RBBP4-1 and
RBBP4-3) constructs was measured in a
CyQuant assay.
(D) Western blot shows RBBP4 and MGMT in
T98GshNT compared with T98GshRBBP4 cells
stably expressing pCDNA3 vector or an shRNA-
resistant pCDNA3-RBBP4 expression construct
(clones R1–R5).
(E) TMZ sensitivity in T98GshNT compared with
T98GshRBBP4 reconstituted with either pCDNA3
or shRNA-resistant RBBP4 (clones R1 and R4).
Shown in each bar graph are the data from three
independent experiments conducted in triplicate
(error bar, SEM; *p < 0.05).reported previously. Because MGMT is critical for TMZ
response (Hegi et al., 2005; Kitange et al., 2009a, 2009b), we
evaluated whether RBBP4 modulates TMZ response through
regulation of MGMT expression in unmethylated GBM cells.
All four RBBP4 shRNAs significantly suppressed MGMT
mRNA level in T98G cells compared to control T98GshNT cells
(Figure 2A). Consistently, suppression of MGMT mRNA was
coupled with decreased MGMT protein levels (Figure 2B),
and knockdown of RBBP4 also suppressed MGMT expression
in U138 (Figures S1A and S1B) and GBM6 cells (see
Figure S6A).
To test whether suppression of MGMT is responsible for the
TMZ sensitivity associated with RBBP4 knockdown, we
treated T98GshNT and T98G cells with two different RBBP4
shRNA constructs (T98GshRBBP4-1 and shRBBP4-3) withCell Reports 14, 2587–2598TMZ alone or in combination with the
MGMT inhibitor O6-benzylguanine (O6-
BG). As expected, O6-BG sensitized
T98GNT cells to TMZ (p < 0.001), but,
in contrast, the addition of O6-BG did
not significantly enhance TMZ sensitivity
in T98GshRBBP4-3 (p = 0.237). Consis-
tent with incomplete suppression of
MGMT mRNA expression (see Fig-
ure 2A), the addition of O6-BG further
sensitized T98GshRBBP4-1 cells (p <
0.05; Figure 2C). In subsequent sub-
cloning, we found heterogeneity in
T98GshRBBP4-1 sub-clones with more
robust RBBP4 suppression associated
with very low MGMT levels (data not
shown). Thus, RBBP4 negatively modu-lates TMZ sensitivity through transcriptional regulation of
MGMT in GBM cells.
To solidify this view, we first evaluated whether re-expression
of an shRNA-resistant RBBP4 construct in T98GshRBBP4-3
clone (from here onward referred to as T98GshRBBP4) would
rescue the expression of MGMT and reverse TMZ sensitivity.
As expected, re-expression of RBBP4 restored MGMT expres-
sion in T98GshRBBP4 cells (Figure 2D). Two of the reconstituted
clones (T98GshRBBP4_R1 and R4) were selected for further
testing. In comparison to the T98GshNT cells, T98GshRBBP4
cells expressing an empty vector (T98GshRBBP4_pcDNA3)
were significantly sensitive to 30 and 100 mM TMZ (p < 0.001;
Figure 2E). Conversely, re-expression of RBBP4 significantly
restored TMZ resistance in T98GshRBBP4_R1 and R4 clones
(p < 0.001 for each clone compared to T98GshRBBP4_pcDNA3;, March 22, 2016 ª2016 The Authors 2589
Figure 3. RBBP4 Modulates Repair of TMZ-
InducedDNADamage andRegulatesRAD51
Expression Level in GBM cells
(A) Western blot depicts the time course activa-
tion of DNA damage signaling following TMZ
comparing T98GshNT and T98GshRBBP4-3
clone.
(B) Nuclear p-H2AX foci in response to 72-hr
exposure of T98G cells expressing shNT
compared with shRBBP4-3 clone (upper panel).
The lower panel shows the fraction of cells with
mean g-H2AX foci of three experiments conducted
in triplicate.
(C) Effect of RBBP4 disruption by shRNA clone
shRBBP4 on PARP inhibitor ABT-888 sensitization
in T98G GBM cells was measured in a CyQuant
assay.
(D) Real-time PCR shows RAD51 and BRCA1
expression in T98GshNT cells compared to
T98GshRBBP4.
(E) Real-time PCR evaluates RAD51 expression
comparing T98GshRBBP4_pCDNA3 with the
RBBP4-reconstituted T98GshRBBP4_R1 and _R4
cells.
(F) CyQuant evaluation shows ABT-888 sensitivity
after RBBP4 reconstitution in T98GshRBBP4
clone compared with the T98GshRBBP4_pcDNA3
and T98GshNT cells (error bar, SEM; *p < 0.05).Figure 2E). Therefore, RBBP4 modulates TMZ response through
transcriptional regulation of MGMT in unmethylated GBM cells.
The Functional Disruption of RBBP4 Enhances TMZ-
Induced DNA Damage
To further evaluatepotentialmechanismsof enhancedTMZcyto-
toxicity in the RBBP4 knockdown cells, we tested the impact on
DNA damage signaling and repair. As shown in Figure 3A, TMZ
treatment induced a similar level of damage signaling 24 hr later
in both T98GshNT and T98GshRBBP4 cells; but, by 72 hr, there
was a marked increase in damage signaling to KAP1, CHK1,
and CHK2 only in the T98GshRBBP4 cells. In contrast, the DNA
damage response signaling was almost back to basal levels by
72 hr in the T98GshNT cells, suggesting that disruption of
RBBP4suppressed repair of TMZ-induceddouble-strandbreaks2590 Cell Reports 14, 2587–2598, March 22, 2016 ª2016 The Authors(DSBs). Consistent with a role in the repair
of DSBs, TMZ-induced gH2AX foci were
significantly higher in T98GshRBBP4
than in the T98shNT cells (p < 0.001; Fig-
ures 3A and 3B).
Since TMZ-induced DSBs are primarily
repaired through HR (Roos et al., 2009),
wenext evaluatedwhetherRBBP4disrup-
tion can compromise HR proficiency in
T98G cells. For this, we employed a
recently established paradigm whereby
HR deficiency results in synthetic lethality
with PARP inhibition (Clark et al., 2012;
Dedes et al., 2011). Consistent with HR
deficiency, T98GshRBBP4 cells weresignificantly sensitized to the PARP inhibitor ABT-888, while
sensitization was not observed in T98GshNT cells (p < 0.0001;
Figure 3C). Next we evaluated the possiblemechanism by exam-
ining the effect of RBBP4 disruption on the expression of RAD51
andBRCA1, two key components of theHRpathway (Stark et al.,
2002). Asshown inFigure 3D,RAD51expressionwassignificantly
downregulated in T98GshRBBP4 relative to the T98GshNT cells
(p = 0.01). In contrast, RBBP4 disruption did not significantly alter
the expression of BRCA1 relative to T98GshNT cells (Figure 3D).
Similar levels of RAD51 suppression were observed with
shRBBP4 inU138,GBM22 (FiguresS2AandS2B), andU251cells
(see Figure 7A). Moreover, re-expression of an shRNA-resistant
RBBP4 construct restored RAD51 expression (Figure 3E) and
reversedABT-888 sensitivity inT98GshRBBP4_R1andR4clones
(p < 0.001; Figure 3F). Collectively, these findings suggest that
Figure 4. RBBP4 Regulates H3K9Ac and Binds MGMT and RAD51
Promoters in Complex with p300
(A) ChIP evaluating the H3K9Ac and H3K9me3 levels within MGMT promoter
region, comparing T98GshNT and T98GshRBBP4 cells, is shown.
(B) ChIP evaluating recruitment of SP1, C-JUN, NF-kB (p65), and H3K9Ac to
bind MGMT promoter region, comparing T98GshNT and T98G-shRBBP4
cells, is shown.
(C) ChIP assessing the recruitment of E2F1 to the RAD51 promoter in
T98GshNT compared with T98GshRBBP4 cells is shown.
(D) ChIP evaluating RBBP4 and p300 recruitment to the MGMT promoter in
T98GshNT compared with T98GRBBP4 cells is shown.
(E and F) RBBP4 and p300 ChIP re-ChIP depicts co-occupancy of RBBP4
within the (E) MGMT promoter region and (F) the RAD51 promoter.RBBP4modulates repair of TMZ-inducedDNAdamage, possibly
through regulation of RAD51. Interestingly, RBBP4 disruption
also significantly sensitized T98G cells to lomustine (CCNU) and
the radiomimetic bleomycin, but did not affect T98G response
to hydroxyurea or cisplatin (Figures S1C–S1E), suggesting that
RBBP4 knockdown does not indiscriminately sensitize cells to
DNA-damaging agents.
RBBP4 Mediates Epigenetic Regulation of MGMT and
RAD51
Even though the majority of studies have associated RBBP4
with transcriptional repression (Kuzmichev et al., 2002; ToddCelland Picketts, 2012; Vermaak et al., 1999), this protein also
has been implicated in transcriptional activation in a complex
with the histone acetyltransferase p300 (Zhang et al., 2000).
Since our findings suggest that RBBP4 may play a role in the
transcriptional activation of MGMT and RAD51, we hypothe-
sized that RBBP4 is recruited to MGMT and RAD51 promoters
as part of this complex to enhance transcription through his-
tone modification, including acetylation of lysine 9 of histone
H3 (H3K9Ac). To test this hypothesis, we evaluated the impact
of RBBP4 knockdown on the prevalence of H3K9Ac within the
MGMT promoter. As shown by chromatin immunoprecipitation
(ChIP), MGMT expression in T98GshNT was associated with
high H3K9Ac levels within the MGMT promoter region (Fig-
ure 4A, left upper panel), while suppression of MGMT expres-
sion in the T98GshRBBP4 cells was accompanied by loss of
H3K9Ac from the MGMT promoter (left lower panel). The loss
of H3K9Ac observed in T98GshRBBP4 cells was coupled
with an increase of H3K9 tri-methylation (H3K9me3) mark
within the MGMT promoter region (Figure 4A, right panel).
H3K9Ac-based ChIP sequencing (ChIP-seq) comparing
T98GshNT with T98GshRBBP4 cells revealed similar changes
in H3K9Ac marks within the RAD51 promoter (Figure S2C).
Beside H3K9Ac and H3K9me3, RBBP4 disruption also sup-
pressed other histone marks associated with open chromatin
within the MGMT promoter region (see Figure S5B). Thus,
RBBP4 is involved in the epigenetic regulation of both MGMT
and RAD51.
We hypothesized that chromatin condensation modulated by
RBBP4 loss resulted in the exclusion of transcription factors
fromMGMT and RAD51 promoters. MGMT expression is mainly
regulated by SP1, C-JUN, and NF-kB transcription factors (Bha-
kat andMitra, 2000; Kitange et al., 2012), while RAD51 transcrip-
tion is modulated by E2F transcription factors (Ogiwara and
Kohno, 2012). In comparing T98GshNT with T98GshRBBP4
cells, SP1, C-JUN, and NF-kB (p65) transcription factors were
all recruited to bind the MGMT promoter in the control
T98GshNT cells, whereas transcription factor binding was sup-
pressed in T98GshRBBP4 cells (Figure 4B). Similarly, the binding
of E2F1 within the RAD51 promoter was exclusively observed in
the T98GshNT cells (Figure 4C). Thus, RBBP4 facilitates acetyla-
tion of histones to maintain open chromatin within promoter
regions that allows transcription factors to bind and drive
MGMT and RAD51 expression.
RBBP4 and p300 Form a Complex that Binds MGMT and
RAD51 Promoters
A previous study has shown that RBBP4 interacts with CBP/
p300 to form a complex involved in histone acetylation (Zhang
et al., 2000); however, whether this specific complex binds the
MGMT promoter region is unknown. We hypothesized that if
RBBP4 and p300 are recruited toMGMT in a common complex,
knockdown of RBBP4 should result in loss of p300 binding to the
MGMT promoter region. Consistently, as shown by ChIP assay,
both RBBP4 and p300 bound the MGMT promoter in the
T98shNT cells (Figure 4D, left upper panel), whereas, in
T98GshRBBP4 cells, loss of RBBP4 was accompanied by a
loss of p300 enrichment within theMGMT promoter region (Fig-
ure 4D, left lower panel). Together, these findings suggest thatReports 14, 2587–2598, March 22, 2016 ª2016 The Authors 2591
RBBP4 and p300 are likely recruited to bind theMGMT promoter
region in a conjoined complex.
To support this view, we performed sequential ChIP (ChIP re-
ChIP). As shown in Figure 4E, an initial RBBP4 and p300 ChIP
demonstrated recruitment of these proteins to the MGMT pro-
moter in the T98GshNT cells (middle panel). Subsequently,
p300-bound chromatin was re-ChIPed from the original
RBBP4 ChIP (Figure 4E, left lower panel), and, conversely,
RBBP4-bound chromatin was re-ChIPed from the original
p300 ChIP (Figure 4E, right lower panel). Since CBP is known
to interact with p300, an antibody against this protein was
included as an additional positive control for the re-ChIP per-
formed on p300-bound chromatin (Figure 4E, left lower panel).
Similar results were observed for RAD51 promoter (Figure 4F).
Consistent with our hypothesis that RBBP4 functions in a com-
plex with p300, the p300 inhibitor C646 suppressed MGMT
expression and sensitized cells to TMZ (see Figures S5C and
S5D). Collectively, these findings strongly support the idea that
the RBBP4/p300 complex binds the MGMT and RAD51 pro-
moters to drive expression in GBM cells.
Dual Effects of RBBP4 on Global Gene Transcription
in GBM
Even though many studies have linked RBBP4 protein with tran-
scriptional repression (Kuzmichev et al., 2002; Todd and Pick-
etts, 2012; Vermaak et al., 1999), to the best of our knowledge,
we are only aware of a single study that has shown that
RBBP4 can interact with CBP/p300 and enhance transcription
through histone acetylation (Zhang et al., 2000). Furthermore,
an understanding of the effect of RBBP4 on global gene expres-
sion is lacking. Thus, we used RNA sequencing (RNA-seq) to
globally identify genes significantly altered by the disruption of
RBBP4 in T98GshNT compared with T98GshRBBP4. RNA-seq
revealed that, after silencing RBBP4, the expression of 1,065
genes was significantly altered, with 671 (63%) genes upregu-
lated and 394 (37%) suppressed (Figure S3A; Tables S1 and
S2). RBBP4 knockdown affected genes involved in a variety of
cellular functions (Tables S3 and S4). The top 20 ontologies en-
riched within the under-expressed genes are shown in Fig-
ure S3B and those enriched in the overexpressed genes are
shown in Figure S3C. Consistent with the previously established
role of RBBP4 in chromatin regulation (reviewed in Wolffe et al.,
2000), 6 (30%) of the top 20 downregulated ontologies are
involved in chromatin and/or nucleosome assembly (Figure S3B,
arrows). Importantly, RBBP4 disruption suppressed genes en-
coding for histones and histone chaperones including NASP,
H2AFY2, and H3F3A (Table S1).
Next we performed ChIP-seq to gain insight into how RBBP4
regulates genes identified through RNA-seq. The H3K9Ac ChIP-
seq analysis demonstrated that, of the 394 downregulated
genes, 162 (41%) genes had reduced H3K9Ac, with an average
H3K9Ac normalized tag density (NTD) within 8-kb windows of
0.069 ± 0.084 (red line in Figure 5A), whereas 301 of 671 (45%)
upregulated genes had an increased H3K9Ac mark, with the
average H3K9Ac NTD of 0.168 ± 0.066 (red line in Figure 5B).
The average binding density around TSS (TSS ± 4 kb) was signif-
icantly different between T98GshRBBP4 and T98GshNT cells for
genes that were up- or downregulated (p value < 2.2e16).2592 Cell Reports 14, 2587–2598, March 22, 2016 ª2016 The AuthorTherefore, RBBP4 regulation of gene expression is mediated
through histone modifications favoring chromatin decondensa-
tion (for upregulated genes) or condensation (for suppressed
genes). The top 20 suppressed andr upregulated genes by
RNA-seq are shown in Figures 5C and 5D, respectively. Repre-
sentative examples of H3K9Ac mark alteration by ChIP-seq
within the 50 region of a downregulated gene (PREX2) and an up-
regulated gene (LOC339535) are shown in Figures 5E and 5F,
respectively.
Interestingly, Fidgetin-like 1 (FIGNL1) and Eye absence homo-
log 1 (EYA1), which are genes involved in DNA repair (Cook et al.,
2009; Stucki, 2009; Yuan and Chen, 2013), were among the
genes suppressed by RBBP4 disruption in association with
loss of H3K9Ac marks within their promoters (Figures 6A and
6B). In contrast, the expression of other key DNA repair genes
was not affected by the RBBP4 status (Figure S2D). Since
EYA1 plays a key role in DNA repair through de-phosphorylation
of tyrosine 142 of histone H2AX (H2AX-Tyr142) (Cook et al.,
2009), we next examined whether TMZ can induce de-phos-
phorylation of H2AX-Tyr142 and whether this effect was abro-
gated by the RBBP4 disruption. As shown in the upper panel
of Figure 6C, TMZ treatment reduced the phosphorylation of
H2AX Tyr142 in T98GshNT cells while the opposite effect was
observed in T98GshRBBP4. Increased phosphorylation of
H2AX-Tyr142 and H2AX-S139 paralleled an increase in
apoptosis, as indicated by elevated cleaved PARP (Figure 6C,
lower panel). Similarly, suppression of EYA1 and FIGNL1 was
observed in U138 (Figure 6D) and U251 (see Figure 7A) GBM
cells with silenced RBBP4 expression. Thus, RBBP4 can epige-
netically regulate transcription of genes involved in multiple
cellular functions, including EYA1 and FIGNL1 that may be addi-
tional DNA damage repair target genes.
RBBP4 Disruption Suppresses Growth and TMZ
Sensitivity In Vivo
Finally, we disrupted RBBP4 expression in MGMT-methylated
U251 GBM cells to evaluate whether RBBP4 can impact growth
and TMZ sensitivity in vivo. All orthotopic animal studies were
conducted according to a protocol approved by the Mayo Insti-
tutional Animal Care and Use Committee. Consistent with the
above findings, RBBP4 disruption suppressed RAD51, EYA1,
and FIGNL1 in U251 cells (Figure 7A). In addition, in vitro evalu-
ation revealed that U251shRBBP4 cells were significantly more
sensitive to TMZ (30 mM) compared with the control U251shNT
(p < 0.01; Figure 7B). As shown in Figure 7C, flow cytometry
revealed an insignificant difference in cell-cycle distribution
between U251shNT and U251shRBBP4 cells with and
without TMZ exposure, suggesting that TMZ sensitization is
independent of cell-cycle progression. The U251shRBBP4
and U251shNT cells then were used to establish orthotopic
tumors in mice. As shown in Figure 7D, placebo-treated
U251shRBBP4-bearing mice survived significantly longer
compared with the placebo-treated U251shNT mice (median
survival = 47 days versus 67.5 days; p < 0.001). There also
was a corresponding significant survival benefit in TMZ-treated
mice implanted with U251shRBBP4 tumors compared with
U251shNT (p value < 0.001 with censoring of mice still alive at
day 150; Figure 7D). Intracranial tumors from moribund mices
Figure 5. RBBP4 Upregulates and Downre-
gulates Gene Transcription in GBM
(A and B) Representative line graphs display the
H3K9Ac binding tags within an 8-kb region sur-
rounding the transcription start site (TSS) of (A)
under-expressed and (B) overexpressed genes
associated with shRBBP4.
(C) Top 20 genes suppressed by RBBP4 shRNA
(positively regulated by nativeRBBP4) are shown.
(D) Top 20 genes elevated by RBBP4 shRNA
(negatively regulated by native RBBP4) are shown.
(E and F) Representative H3K9Ac ChIP-seq dis-
plays a gene that was (E) suppressed and (F)
elevated by RBBP4 shRNA.demonstrated that RBBP4 knockdown was maintained for the
duration of the in vivo experiment (Figure S7). Similar anti-tumor
effects were observed in the patient-derived GBM6 xenograft
model in which RBBP4 knockdown suppressed growth of un-
treated orthotopic tumors (Figure S6D). These data demonstrate
that RBBP4 suppression is associated with slower tumor growth
and greater TMZ sensitivity in GBM orthotopic xenografts.
DISCUSSION
Epigenetic regulation of chromatin structure is an important
modulator of gene expression and can critically influence tumor
biology and response to therapies. In many tumor types, muta-
tions or altered expression of the epigenetic regulators have
been directly implicated in tumorigenesis through their effects
on gene expression (Turcan et al., 2012; Venneti et al., 2013; re-
viewed in Wilting and Dannenberg, 2012), and this has stimu-Cell Reports 14, 2587–2598lated significant interest in developing
pharmacologic inhibitors of these regula-
tors. The two best examples of this para-
digm include BRD4 and the HDAC family
of proteins for which there are now
several inhibitors that are either clinically
approved or in clinical testing (Fiskus
et al., 2014b). More recent data also sug-
gest that HDACs or BRD4 are important
regulators of therapeutic resistance
emergence (Fiskus et al., 2014a; Kitange
et al., 2012; Knoechel et al., 2014; Tang
et al., 2014). Similar to these two targets,
this paper reports the importance of the
epigenetic regulator RBBP4 in the regula-
tion of gene expression patterns in human
GBM tumor cells. Knockdown of RBBP4
resulted in marked sensitization of tumor
cells to TMZ in conjunction with suppres-
sion of several DNA repair genes known
to be critical for response to TMZ
chemotherapy.
MGMT is a critical mediator of cytotox-
icity for DNA-alkylating agents such as
TMZ (Hegi et al., 2005; Kitange et al.,
2009b, 2012), and either direct MGMTknockdown or treatment with an MGMT inhibitor can markedly
sensitize tumors to TMZ therapy (Hirose et al., 2003; Vlachoster-
gios et al., 2013). Thus, the suppression of MGMT associated
with RBBP4 shRNA expression can be mechanistically linked
to the enhanced TMZ sensitivity seen in T98G and U138 cells.
Unrepaired TMZ-induced O6-MG lesions are mispaired with
thymidine and result in MMR-mediated stalled replication forks
that ultimately degenerate into DSBs (Hirose et al., 2001; Sarka-
ria et al., 2008). The replication-associated DSBs are preferably
repaired by the HR system (Chai et al., 2014; Tentori et al., 2014;
Yoshimoto et al., 2012), and cells lacking proficient HR are highly
sensitive to TMZ-induced damage (Liu et al., 2009; Short et al.,
2011). RAD51 is a key component of the HR pathway, and,
consistent with a significant defect in HR integrity, suppression
of RBBP4 resulted both in a significant reduction in RAD51
expression and increased sensitivity to PARP inhibition (Fig-
ure 3C). While suppression of additional HR components may, March 22, 2016 ª2016 The Authors 2593
Figure 6. RBBP4 Regulates the Expression
of FIGNL1 and EYA1
(A) RNA-seq was performed using RNA extracted
from T98GshNT and T98GshRBBP4 constructs
and shown are the gene counts for FIGNL1
and EYA1.
(B) ChIP-seq displays H3K9Ac marks within
FIGNL1 (upper panel) and EYA1 (lower panel)
promoter regions.
(C) Upper panel shows the effect of shRBBP4 on
TMZ-induced p-H2AX (Y142) and p-H2AX (S139),
whereas the lower panel depicts the effect on
cleaved PARP.
(D) RBBP4, FIGNL1, and EYA1 expression in U138
cells expressing shNT is compared with shRBBP4.
(E) A proposed model of RBBP4 associated with
CBP/p300, which leads to histone acetylation and
an open chromatin structure that facilitates tran-
scription factor binding and expression of target
genes, is shown.contribute to the repair defects, these data demonstrate a similar
effect as previous studies, where RAD51 knockdown was asso-
ciated with an enhanced response to TMZ chemotherapy (Short
et al., 2011; Zhang et al., 2012). This effect may be especially
important in tumors that lack significant MGMT expression,
such as GBM12, GBM22 (Figure 1B), and U251 (Figure 7), where
unrepaired O6-MG lesions result in markedly higher levels of
replication stress and efficient processing of replication-induced
lesions is critical for cell survival. High levels of TMZ-induced
replication stress and DSBs are more likely to be observed in
highly proliferating cells, while RBBP4 disruption suppressed
proliferation potential in GBM cells (Figure 7C; Figure S6). This
effect on reduced proliferation might be mediated through
induction of cell differentiation, as suggested by suppressed
neurosphere formation in GBM6shRBBP4-expressing cells (Fig-
ure S6B). Delineation of RBBP4 as an important mediator of two
major known mechanisms of repair of TMZ-induced DNA dam-
age suggests that the relevant RBBP4 complex mediating these
effects may be an attractive therapeutic target.2594 Cell Reports 14, 2587–2598, March 22, 2016 ª2016 The AuthorsThe influence of RBBP4 on HR may be
an important regulatory mechanism that
is relevant across multiple tumor types.
As described previously, synthetic
lethality to PARP inhibition is a hallmark
of HR deficiency (Clark et al., 2012;
Dedes et al., 2011), and the significant
sensitivity of T98G cells to either ABT-
888 or BMN673 (Figure 3C; data not
shown) is consistent with physiologically
meaningful defects in HR. Beyond sup-
pression of RAD51 expression, RBBP4
knockdown also reduced gene expres-
sion of EYA1 and FIGNL1, which recently
were demonstrated to play a key role in
the repair of DSBs and apoptosis (Cook
et al., 2009; Yuan and Chen, 2013).
Moreover, beyond regulating geneexpression, RBBP4 may regulate HR more directly, since this
protein can co-associate with a BRCT domain within BRCA1
(Yarden and Brody, 1999). RBBP4 also is an integral compo-
nent of the NURD complex, and, another member of this com-
plex, chromodomain helicase DNA-binding protein 4 (CHD4),
indirectly regulates BRCA1 recruitment to DNA DSBs, and a
lack of CHD4 promotes sensitivity to PARP inhibitors (Pan
et al., 2012). Figure S1 shows that RBBP4 knockdown was
associated with increased sensitivity to the radio-mimetic bleo-
mycin, which is in contrast to a previous study that demon-
strated an increased sensitivity to ionizing radiation with
RBBP4 overexpression (Torres-Roca et al., 2005). These
apparently contradictory results suggest that either suppres-
sion or overexpression of RBBP4 can deregulate critical DNA
repair capacities and lead to increased cytotoxicity. Future
studies will be directed at dissecting the relative contributions
to DNA repair deficits conferred by the effects of RBBP4 on
gene expression versus direct interactions with DNA repair
complexes.
Figure 7. RBBP4 Disruption in U251 Suppresses Growth and
Enhances TMZ Sensitivity In Vivo
(A) The qRT-PCR shows expression of RAD51, EYA1, and FIGNL1 in U251
cells expressing RBBP4shRNA.
(B) U251shRBBP4 and control U251shNT cells were treated with 0 or 30 mM
TMZ and confluence was monitored using Incucyte live-cell imaging. The bar
graph displays the mean of three experiments conducted independently in
triplicate (error bar, SEM; **p < 0.05).
(C) Cell-cycle evaluation was performed using U251shRBBP4 and control
U251shNT following 72 hr exposure to 0 or 30 mM TMZ (error bar, SEM).
(D) Kaplan-Meier survival plots depict the in vivo growth and TMZ sensitivity of
control U251shNT compared with the U251RBBP4 cells (PL, placebo; *p <
0.001 and **p < 0.05).The effects of RBBP4 on global gene expression patterns have
not been elucidated. Comparison of gene expression in T98G
cells expressing RBBP4 shRNA versus non-targeted shRNA re-
vealed that RBBP4 exerts a suppressive effect on almost two-
thirds of the genes with altered expression, while expressions
of the remaining genes are upregulated. Consistent with disrup-
tion of an RBBP4/p300/CBP complex by shRBBP4 expression,
41% of the 394 downregulated genes had specific suppression
of H3K9Ac within their promoters. This change in the chromatin
landscape was most pronounced within an 8-kb region encom-
passing the TSS. A similar study using direct ChIP-seq analysis
of CBP/p300 binding in T98G cells demonstrated preferential
binding within the TSS and transcript ends (Ramos et al.,
2010). Moreover, in their study, a total of 170 genes (including
MGMT) within the TSS bound by the p300/CBP also were alteredCellin shRBBP4-expressing T98G cells in our current dataset. In
conjunction with the ChIP-re-ChIP data demonstrating co-asso-
ciation of RBBP4 and p300/CBP within the same promoter re-
gions of MGMT and RAD51 and the effects of RBBP4 shRNA
on p300 within these regions, these data strongly support the
concept that RBBP4 and CBP/p300 exist in a complex that
can effectively modulate gene expression (Figure 6E). CBP/
p300 has important HAT activity and can acetylate several sites
within histone tails including H3K9. Overall, histone acetylation
mediated by CBP/p300 promotes an open chromatin structure
conducive to gene expression. Thus, the associations of
RBBP4 shRNA with both reduced H3K9Ac and reduced tran-
scription factor binding within the MGMT and RAD51 promoters
are all consistent with a model where RBBP4/CBP/p300
promotes an open chromatin structure that allows transcription
factor binding and effective gene expression of multiple gene
targets. Since the current ChIP-seq data are based on a single
histonemark, there is a possibility that the identified genes repre-
sent only a fraction of genes regulated by the RBBP4/CBP/p300
complex. This is particularly notable since MGMT was signifi-
cantly silenced after RBBP4 disruption despite low baseline
levels of H3K9Ac tags within the promoter region (Figure S5A),
which suggests other histone marks modulated by RBBP4 also
may be important in mediating MGMT regulation. Consistent
with this view, RBBP4 disruption elevatedmultiple histonemarks
favoring closed chromatin within the MGMT promoter (Fig-
ure S5B). Thus, fine mapping of the chromatin landscape regu-
lated by the RBBP4/CBP/p300 complex using multiple histone
marks is a subject for further investigation.
Analysis of the data for enriched gene ontologies regulated by
RBBP4 indicates that several of these ontologies are related to
nucleosome assembly, cell-cycle progression, angiogenesis,
and cell survival. Consistently, nucleosome assembly and cell-
cycle progression also were ontologies shown to be highly en-
riched upon suppression of CBP/p300 activity in melanoma cells
(Yan et al., 2013). In this latter study, the p300 HAT inhibitor C646
also suppressed pathways associated with DNA damage check-
points and repair. Consistently, p300 inhibitor C646 suppressed
MGMT expression and sensitized TMZ in T98G cells in the pre-
sent study (Figures S5C and S5D). Since RBBP4 regulates mul-
tiple gene pathways involved in gliomagenesis, we queried the
Oncomine database (https://www.oncomine.org/resource/) to
evaluate whether this gene is overexpressed in gliomas. Intrigu-
ingly, RBBP4 is overexpressed in glial tumors with the highest
expression in GBM (Figures S4A and S4B). In a follow-up anal-
ysis of The Cancer Genome Atlas (TCGA) mRNA expression
data, RBBP4 expression directly correlated with the expression
of RAD51 and FIGNL1 in all patients, while a significant correla-
tion with EYA1 was specifically observed in unmethylated GBM
(Figure S4C). Conversely, RBBP4 expression negatively corre-
lated with MGMT levels in methylated, whereas no significant
correlation was noted in unmethylated tumors. These findings
are consistent with a view that RBBP4 may be a part of multiple
epigenetic mechanisms regulating MGMT in GBM. Overall,
RBBP4 expression did not correlate with survival of GBM pa-
tients within TCGA database (Figure S4D). In an analysis segre-
gated by GBM sub-type, low RBBP4 expression marginally
associated with a better survival outcome for mesenchymalReports 14, 2587–2598, March 22, 2016 ª2016 The Authors 2595
and neural GBM subclasses (p = 0.05; data not shown). These
findings are in part consistent with the current results showing
that RBBP4 knockdown in U251 can significantly prolong
survival of both placebo- and TMZ-treated orthotopic tumors
(Figure 7C) and prolongs survival of untreated GBM6 orthotopic
tumors (Figure S6D). Thus, besides modulating therapy
response, RBBP4 also may control tumor growth, perhaps
through cell proliferation, angiogenesis, or other unknownmech-
anisms. Future studies are focused on extending these observa-
tions to our panel of patient-derived xenograft models to define
the influence of RBBP4 on gene expression and therapy
response across a spectrum of GBMs. These studieswill provide
critical insight into the role of RBBP4 both in tumorigenesis and
therapeutic resistance.
In summary, our study provides description of a role for
RBBP4 in the regulation of TMZ sensitivity. Of particular transla-
tional interest is the finding that RBBP4 interacts with CBP/p300
to form a complex that drives the expression of MGMT, RAD51,
and other selected DNA repair genes through histone acetyla-
tion. Particularly, since MGMT is overexpressed in 70% of
GBM and given the ongoing interest in developing therapies
targeting HATs, the RBBP4/CBP/p300 complex poses an inter-
esting target for future therapies in GBM.
EXPERIMENTAL PROCEDURES
Cell Culture and Drug Cytotoxicity Assay
Short-term primary serum-free cultures were derived from the flank GBM xe-
nografts as described previously by our group (Carlson et al., 2011), and the
neuro-sphere formation assay was performed as previously reported (Kitange
et al., 2012). Additional culture procedures are provided in the Supplemental
Experimental Procedures.
Gene Knockdown and Re-expression
pGIPZ-lentiviral vectors targeting human RBBP4 gene (see the Supplemental
Experimental Procedures) and NT pGIPZ control vector were purchased from
Mayo Clinic RNA interference shared resource. Lentiviral shRNA pseudo-par-
ticles were produced by co-transfection of the Trans-Lentiviral packaging mix
(GE Dharmacon) with shRNA transfer vector into HEK293T packaging cells.
Cells were transduced with the lentiviral particles followed by puromycin se-
lection (2–5 mg/ml) for 10 days. The shRNA-resistant Myc3-tagged RBBP4
pCDNA3 construct (Plasmid 20715) was purchased from Addgene. The trans-
fections were conducted as previously reported (Kitange et al., 2010) and
selection was performed using 1 mg/ml G418 (Life Technologies).
Western Blotting
Total proteins were isolated by lysing cells in a detergent-containing radio-
immunoprecipitation assay (RIPA) buffer (Sigma) supplemented with a cocktail
of protease inhibitors (Roche), while total histone extraction was performed
using an Epigenetek kit. The subsequent steps were performed as previously
reported (Kitange et al., 2012).
Real-Time RT-PCR
Real-time PCRwas performed as previously reported (Kitange et al., 2012) and
additional procedures are included in the Supplemental Experimental
Procedures.
ChIP and Re-ChIP
ChIP was performed using the EZ-ChIP kit (Millipore). Crosslinking was per-
formed with 1% formaldehyde at room temperature for 10 min and was
quenched with 0.1 M glycine for 5 min. Subsequent steps were performed
as previously reported (Kitange et al., 2012). The ChIP-re-ChIP experiments
were performed according to the manufacturer’s instructions (Active Motif).2596 Cell Reports 14, 2587–2598, March 22, 2016 ª2016 The AuthorRNA-Seq and ChIP-Seq
To identify RBBP4 target genes, RNA-seq and ChIP-seq were conducted
comparing T98GshNT with T98GshRBBP4 cells. The subsequent steps for
RNA-seq and ChIP-seq procedures are described in the Supplemental Exper-
imental Procedures.
Statistical Analysis
The differences in TMZ sensitivity and mRNA expression in relation to RBBP4
expression status were analyzed using a two-sample t test, and a p value <
0.05 was considered statistically significant. The in vivo survival was evaluated
using Kaplan-Meier survival plots and log-rank test was used for statistical sig-
nificance. Additional statistical analyses are described in the Supplemental
Experimental Procedures.
ACCESSION NUMBERS
The accession number for both the RNA-seq and ChIP-seq data reported in
this paper is GEO: GSE72477.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.02.045.
AUTHORS CONTRIBUTIONS
G.J.K. performed experiments, analyzed data, and wrote the manuscript.
A.C.M. evaluated TMZ sensitivity in RBBP4-reconstituted clones. M.A.S. har-
vested cells for primary cultures used in this study. J.C.P. performed p-H2AX
foci experiments. B.L.C. harvested cells for primary cultures used in this study.
Y.Z. analyzed shRNA screening data. A.A.N. analyzed RNA-seq data. J.-H.L.
performed ChIP-seq. H.Y. analyzed ChIP-seq data. P.A.D. performed TCGA
analysis in relation to RBBP4. Z.Z. supervised ChIP-seq and edited the manu-
script. J.N.S. supervised the study and edited the manuscript.
ACKNOWLEDGMENTS
We thank Dr. Yuichi Machida, Department of Oncology Research, Mayo Clinic,
Rochester, for supplying the shRNA library and Dr. Shiv Gupta, Department of
Radiation Oncology Research, Mayo Clinic, Rochester, for reading and critical
comments on the manuscript. The project was supported by funding from the
American Cancer Society (G.J.K.), NIH RO1CA176830 (J.N.S.), and the Mayo
Brain Tumor SPORE (P50 CA108961).
Received: March 4, 2015
Revised: December 22, 2015
Accepted: February 4, 2016
Published: March 10, 2016
REFERENCES
Bhakat, K.K., and Mitra, S. (2000). Regulation of the human O(6)-methylgua-
nine-DNA methyltransferase gene by transcriptional coactivators cAMP
response element-binding protein-binding protein and p300. J. Biol. Chem.
275, 34197–34204.
Cahill, D.P., Codd, P.J., Batchelor, T.T., Curry, W.T., and Louis, D.N. (2008).
MSH6 inactivation and emergent temozolomide resistance in human glioblas-
tomas. Clin. Neurosurg. 55, 165–171.
Carlson, B.L., Pokorny, J.L., Schroeder,M.A., and Sarkaria, J.N. (2011). Estab-
lishment, maintenance and in vitro and in vivo applications of primary human
glioblastoma multiforme (GBM) xenograft models for translational biology
studies and drug discovery. Curr. Protoc. Pharmacol. Chapter 14, Unit 14.16.
Chai, K.M., Wang, C.Y., Liaw, H.J., Fang, K.M., Yang, C.S., and Tzeng, S.F.
(2014). Downregulation of BRCA1-BRCA2-containing complex subunit 3 sen-
sitizes glioma cells to temozolomide. Oncotarget 5, 10901–10915.s
Clark, C.C., Weitzel, J.N., and O’Connor, T.R. (2012). Enhancement of syn-
thetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin
in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol. Cancer
Ther. 11, 1948–1958.
Cook, P.J., Ju, B.G., Telese, F., Wang, X., Glass, C.K., and Rosenfeld, M.G.
(2009). Tyrosine dephosphorylation of H2AXmodulates apoptosis and survival
decisions. Nature 458, 591–596.
Dedes, K.J., Wilkerson, P.M., Wetterskog, D., Weigelt, B., Ashworth, A., and
Reis-Filho, J.S. (2011). Synthetic lethality of PARP inhibition in cancers lacking
BRCA1 and BRCA2 mutations. Cell Cycle 10, 1192–1199.
Drabløs, F., Feyzi, E., Aas, P.A., Vaagbø, C.B., Kavli, B., Bratlie, M.S., Pen˜a-
Diaz, J., Otterlei, M., Slupphaug, G., and Krokan, H.E. (2004). Alkylation dam-
age in DNA and RNA–repair mechanisms and medical significance. DNA
Repair (Amst.) 3, 1389–1407.
Fiskus, W., Sharma, S., Qi, J., Shah, B., Devaraj, S.G., Leveque, C., Portier,
B.P., Iyer, S., Bradner, J.E., and Bhalla, K.N. (2014a). BET protein antagonist
JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and over-
comes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol. Cancer
Ther. 13, 2315–2327.
Fiskus, W., Sharma, S., Qi, J., Valenta, J.A., Schaub, L.J., Shah, B., Peth, K.,
Portier, B.P., Rodriguez, M., Devaraj, S.G., et al. (2014b). Highly active combi-
nation of BRD4 antagonist and histone deacetylase inhibitor against human
acute myelogenous leukemia cells. Mol. Cancer Ther. 13, 1142–1154.
Furuyama, T., Dalal, Y., and Henikoff, S. (2006). Chaperone-mediated assem-
bly of centromeric chromatin in vitro. Proc. Natl. Acad. Sci. USA 103, 6172–
6177.
Gaspar, N., Marshall, L., Perryman, L., Bax, D.A., Little, S.E., Viana-Pereira, M.,
Sharp, S.Y., Vassal, G., Pearson, A.D., Reis, R.M., et al. (2010). MGMT-inde-
pendent temozolomide resistance in pediatric glioblastoma cells associated
with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res. 70,
9243–9252.
Hegi, M.E., Diserens, A.C., Godard, S., Dietrich, P.Y., Regli, L., Ostermann, S.,
Otten, P., Van Melle, G., de Tribolet, N., and Stupp, R. (2004). Clinical trial sub-
stantiates the predictive value of O-6-methylguanine-DNA methyltransferase
promoter methylation in glioblastoma patients treated with temozolomide.
Clin. Cancer Res. 10, 1871–1874.
Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M.,
Kros, J.M., Hainfellner, J.A., Mason, W., Mariani, L., et al. (2005). MGMT gene
silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352,
997–1003.
Hirose, Y., Berger, M.S., and Pieper, R.O. (2001). p53 effects both the duration
of G2/M arrest and the fate of temozolomide-treated human glioblastoma
cells. Cancer Res. 61, 1957–1963.
Hirose, Y., Kreklau, E.L., Erickson, L.C., Berger, M.S., and Pieper, R.O. (2003).
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in
failure to protect the human glioblastoma cell line SF767 from temozolo-
mide-induced cytotoxicity. J. Neurosurg. 98, 591–598.
Kitange, G.J., Carlson, B.L., Mladek, A.C., Decker, P.A., Schroeder, M.A., Wu,
W., Grogan, P.T., Giannini, C., Ballman, K.V., Buckner, J.C., et al. (2009a).
Evaluation ofMGMTpromoter methylation status and correlation with temozo-
lomide response in orthotopic glioblastoma xenograft model. J. Neurooncol.
92, 23–31.
Kitange, G.J., Carlson, B.L., Schroeder, M.A., Grogan, P.T., Lamont, J.D.,
Decker, P.A., Wu, W., James, C.D., and Sarkaria, J.N. (2009b). Induction of
MGMT expression is associatedwith temozolomide resistance in glioblastoma
xenografts. Neuro-oncol. 11, 281–291.
Kitange, G.J., Carlson, B.L., Schroeder, M.A., Decker, P.A., Morlan, B.W., Wu,
W., Ballman, K.V., Giannini, C., and Sarkaria, J.N. (2010). Expression of CD74
in high grade gliomas: a potential role in temozolomide resistance.
J. Neurooncol. 100, 177–186.
Kitange, G.J., Mladek, A.C., Carlson, B.L., Schroeder, M.A., Pokorny, J.L.,
Cen, L., Decker, P.A., Wu, W., Lomberk, G.A., Gupta, S.K., et al. (2012). Inhi-
bition of histone deacetylation potentiates the evolution of acquired temozolo-Cellmide resistance linked toMGMT upregulation in glioblastoma xenografts. Clin.
Cancer Res. 18, 4070–4079.
Knoechel, B., Roderick, J.E., Williamson, K.E., Zhu, J., Lohr, J.G., Cotton,
M.J., Gillespie, S.M., Fernandez, D., Ku, M., Wang, H., et al. (2014). An epige-
netic mechanism of resistance to targeted therapy in T cell acute lympho-
blastic leukemia. Nat. Genet. 46, 364–370.
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., and Rein-
berg, D. (2002). Histone methyltransferase activity associated with a human
multiprotein complex containing the Enhancer of Zeste protein. Genes Dev.
16, 2893–2905.
Liu, X., Han, E.K., Anderson, M., Shi, Y., Semizarov, D., Wang, G., McGonigal,
T., Roberts, L., Lasko, L., Palma, J., et al. (2009). Acquired resistance to com-
bination treatment with temozolomide and ABT-888 is mediated by both base
excision repair and homologous recombination DNA repair pathways. Mol.
Cancer Res. 7, 1686–1692.
Ogiwara, H., and Kohno, T. (2012). CBP and p300 histone acetyltransferases
contribute to homologous recombination by transcriptionally activating the
BRCA1 and RAD51 genes. PLoS ONE 7, e52810.
Pan, M.R., Hsieh, H.J., Dai, H., Hung, W.C., Li, K., Peng, G., and Lin, S.Y.
(2012). Chromodomain helicase DNA-binding protein 4 (CHD4) regulates
homologous recombination DNA repair, and its deficiency sensitizes cells to
poly(ADP-ribose) polymerase (PARP) inhibitor treatment. J. Biol. Chem. 287,
6764–6772.
Ramos, Y.F., Hestand, M.S., Verlaan, M., Krabbendam, E., Ariyurek, Y., van
Galen, M., van Dam, H., van Ommen, G.J., den Dunnen, J.T., Zantema, A.,
and ’t Hoen, P.A. (2010). Genome-wide assessment of differential roles for
p300 and CBP in transcription regulation. Nucleic Acids Res. 38, 5396–5408.
Roos, W.P., Nikolova, T., Quiros, S., Naumann, S.C., Kiedron, O., Zdzienicka,
M.Z., and Kaina, B. (2009). Brca2/Xrcc2 dependent HR, but not NHEJ, is
required for protection against O(6)-methylguanine triggered apoptosis,
DSBs and chromosomal aberrations by a process leading to SCEs. DNA
Repair (Amst.) 8, 72–86.
Sarkaria, J.N., Kitange, G.J., James, C.D., Plummer, R., Calvert, H., Weller, M.,
and Wick, W. (2008). Mechanisms of chemoresistance to alkylating agents in
malignant glioma. Clin. Cancer Res. 14, 2900–2908.
Short, S.C., Giampieri, S., Worku, M., Alcaide-German, M., Sioftanos, G.,
Bourne, S., Lio, K.I., Shaked-Rabi, M., and Martindale, C. (2011). Rad51 inhi-
bition is an effective means of targeting DNA repair in glioma models and
CD133+ tumor-derived cells. Neuro-oncol. 13, 487–499.
Stark, J.M., Hu, P., Pierce, A.J., Moynahan,M.E., Ellis, N., and Jasin, M. (2002).
ATP hydrolysis by mammalian RAD51 has a key role during homology-
directed DNA repair. J. Biol. Chem. 277, 20185–20194.
Stucki, M. (2009). Histone H2A.X Tyr142 phosphorylation: a novel sWItCH for
apoptosis? DNA Repair (Amst.) 8, 873–876.
Stupp, R., Hegi, M.E., Mason, W.P., van den Bent, M.J., Taphoorn, M.J.,
Janzer, R.C., Ludwin, S.K., Allgeier, A., Fisher, B., Belanger, K., et al.; Euro-
pean Organisation for Research and Treatment of Cancer Brain Tumour and
Radiation OncologyGroups; National Cancer Institute of CanadaClinical Trials
Group (2009). Effects of radiotherapy with concomitant and adjuvant temozo-
lomide versus radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10,
459–466.
Tang, Y., Gholamin, S., Schubert, S., Willardson, M.I., Lee, A., Bandopad-
hayay, P., Bergthold, G., Masoud, S., Nguyen, B., Vue, N., et al. (2014). Epige-
netic targeting of Hedgehog pathway transcriptional output through BET
bromodomain inhibition. Nat. Med. 20, 732–740.
Tentori, L., Ricci-Vitiani, L., Muzi, A., Ciccarone, F., Pelacchi, F., Calabrese, R.,
Runci, D., Pallini, R., Caiafa, P., and Graziani, G. (2014). Pharmacological inhi-
bition of poly(ADP-ribose) polymerase-1 modulates resistance of human
glioblastoma stem cells to temozolomide. BMC Cancer 14, 151.
Todd, M.A., and Picketts, D.J. (2012). PHF6 interacts with the nucleosome re-
modeling and deacetylation (NuRD) complex. J. Proteome Res. 11, 4326–
4337.Reports 14, 2587–2598, March 22, 2016 ª2016 The Authors 2597
Torres-Roca, J.F., Eschrich, S., Zhao, H., Bloom, G., Sung, J., McCarthy, S.,
Cantor, A.B., Scuto, A., Li, C., Zhang, S., et al. (2005). Prediction of radiation
sensitivity using a gene expression classifier. Cancer Res. 65, 7169–7176.
Turcan, S., Rohle, D., Goenka, A., Walsh, L.A., Fang, F., Yilmaz, E., Campos,
C., Fabius, A.W., Lu, C., Ward, P.S., et al. (2012). IDH1 mutation is sufficient to
establish the glioma hypermethylator phenotype. Nature 483, 479–483.
Venneti, S., Garimella, M.T., Sullivan, L.M., Martinez, D., Huse, J.T., Heguy, A.,
Santi, M., Thompson, C.B., and Judkins, A.R. (2013). Evaluation of histone 3
lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric
glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M
mutant glioblastomas. Brain Pathol. 23, 558–564.
Vermaak, D., Wade, P.A., Jones, P.L., Shi, Y.B., andWolffe, A.P. (1999). Func-
tional analysis of the SIN3-histone deacetylase RPD3-RbAp48-histone H4
connection in the Xenopus oocyte. Mol. Cell. Biol. 19, 5847–5860.
Vlachostergios, P.J., Hatzidaki, E., and Papandreou, C.N. (2013). MGMT
repletion after treatment of glioblastoma cells with temozolomide and O6-ben-
zylguanine implicates NFkB and mutant p53. Neurol. Res. 35, 879–882.
Wilting, R.H., and Dannenberg, J.H. (2012). Epigenetic mechanisms in tumor-
igenesis, tumor cell heterogeneity and drug resistance. Drug Resist. Updat. 15,
21–38.
Wolffe, A.P., Urnov, F.D., and Guschin, D. (2000). Co-repressor complexes
and remodelling chromatin for repression. Biochem. Soc. Trans. 28, 379–386.
Yan, G., Eller, M.S., Elm, C., Larocca, C.A., Ryu, B., Panova, I.P., Dancy, B.M.,
Bowers, E.M., Meyers, D., Lareau, L., et al. (2013). Selective inhibition of p300
HAT blocks cell cycle progression, induces cellular senescence, and inhibits2598 Cell Reports 14, 2587–2598, March 22, 2016 ª2016 The Authorthe DNA damage response in melanoma cells. J. Invest. Dermatol. 133,
2444–2452.
Yarden, R.I., and Brody, L.C. (1999). BRCA1 interacts with components of the
histone deacetylase complex. Proc. Natl. Acad. Sci. USA 96, 4983–4988.
Yip, S., Miao, J., Cahill, D.P., Iafrate, A.J., Aldape, K., Nutt, C.L., and Louis,
D.N. (2009). MSH6mutations arise in glioblastomas during temozolomide ther-
apy and mediate temozolomide resistance. Clin. Cancer Res. 15, 4622–4629.
Yoshimoto, K., Mizoguchi, M., Hata, N., Murata, H., Hatae, R., Amano, T., Na-
kamizo, A., and Sasaki, T. (2012). Complex DNA repair pathways as possible
therapeutic targets to overcome temozolomide resistance in glioblastoma.
Front. Oncol. 2, 186.
Yuan, J., and Chen, J. (2013). FIGNL1-containing protein complex is required
for efficient homologous recombination repair. Proc. Natl. Acad. Sci. USA 110,
10640–10645.
Zhang, Q., Vo, N., and Goodman, R.H. (2000). Histone binding protein RbAp48
interacts with a complex of CREB binding protein and phosphorylated CREB.
Mol. Cell. Biol. 20, 4970–4978.
Zhang, N., Wu, X., Yang, L., Xiao, F., Zhang, H., Zhou, A., Huang, Z., and
Huang, S. (2012). FoxM1 inhibition sensitizes resistant glioblastoma cells to te-
mozolomide by downregulating the expression of DNA-repair gene Rad51.
Clin. Cancer Res. 18, 5961–5971.
Zhang, W., Tyl, M., Ward, R., Sobott, F., Maman, J., Murthy, A.S., Watson,
A.A., Fedorov, O., Bowman, A., Owen-Hughes, T., et al. (2013). Structural plas-
ticity of histones H3-H4 facilitates their allosteric exchange between RbAp48
and ASF1. Nat. Struct. Mol. Biol. 20, 29–35.s
